Manchester Interdisciplinary Biocentre, University of Manchester and Manchester Cancer Research Centre, Manchester M13 9PT, U.K.
J Med Chem. 2011 Oct 13;54(19):6597-611. doi: 10.1021/jm200416e. Epub 2011 Sep 13.
Imidazoacridin-6-ones are shown to be potent nanomolar inhibitors of the enzyme NQO2. By use of computational molecular modeling, a reliable QSAR was established, relating inhibitory potency with calculated binding affinity. Further, crystal structures of NQO2 containing two of the imidazoacridin-6-ones have been solved. To generate compounds with reduced off-target (DNA binding) effects, an N-oxide moiety was introduced into the tertiary aminoalkyl side chain of the imidazoacridin-6-ones. This resulted in substantially less toxicity in a panel of eight cancer cell lines, decreased protein binding, and reduced DNA binding and nuclear accumulation. Finally, one of the N-oxides showed potent ability to inhibit the enzymatic function of NQO2 in cells, and therefore, it may be useful as a pharmacological probe to study the properties of the enzyme in vitro and in vivo.
咪唑并吖啶酮类被证明是 NQO2 酶的有效纳摩尔抑制剂。通过使用计算分子建模,建立了一个可靠的定量构效关系,将抑制效力与计算的结合亲和力相关联。此外,还解决了含有两种咪唑并吖啶酮类的 NQO2 的晶体结构。为了生成具有降低的非靶标(DNA 结合)效应的化合物,将 N-氧化物部分引入咪唑并吖啶酮类的叔氨基烷基侧链中。这导致在八种癌细胞系的毒性显著降低,蛋白结合减少,DNA 结合和核积累减少。最后,一种 N-氧化物显示出抑制 NQO2 酶在细胞中的酶促功能的有效能力,因此,它可能作为药理学探针有用,用于研究酶在体外和体内的特性。